<DOC>
	<DOCNO>NCT02587962</DOCNO>
	<brief_summary>An ascend dose study patient solid tumor evaluate safety , tolerability , pharmacodynamics efficacy birinapant give combination pembrolizumab .</brief_summary>
	<brief_title>Dose-escalation Study Birinapant Pembrolizumab Solid Tumors</brief_title>
	<detailed_description>This study conduct two phase . The Phase 1 portion study employ sequential group dose-escalation design determine dose-limiting toxicity ( DLT ) recommend Phase 2 dose ( RP2D ) birinapant administer combination 200 mg pembrolizumab , administer 30-minute intravenous ( IV ) infusion . The follow proposed dos birinapant evaluate : 5.6 , 11 , 17 , 22 mg/m2 The Phase 2 portion study ass safety tolerability RP2D birinapant give combination pembrolizumab .</detailed_description>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically confirm solid malignancy metastatic unresectable standard curative palliative measure exist longer effective Measurable disease accord RECIST v 1.1 Eastern Cooperative Oncology Group ( ECOG ) score 0 1 Normal organ marrow function Prior monoclonal antibody , chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior Screening . Patients receive investigational agent within 30 day first dose study drug . Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody . History allergic reaction attribute compound similar chemical biologic composition birinapant pembrolizumab constituent . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , hypertension , unstable angina pectoris , cardiac arrhythmia , autoimmune disease inflammatory disease , psychiatric illness/social situation would limit compliance study requirement . Evidence active , noninfectious pneumonitis history interstitial lung disease . Known active infection require systemic therapy , include HIV , hepatitis B , hepatitis C. Currently breast feeding , pregnant plan become pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>